Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Plasma Cell Disorders

High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis

Bone Marrow Transplantation volume 50, pages 668–672 (2015)Cite this article

Subjects

Abstract

Cardiac involvement in light-chain amyloidosis (AL) predicts poor prognosis and is associated with higher TRM and morbidity during high-dose therapy and auto-SCT (HDT–ASCT). We studied the outcomes of 30 patients with cardiac amyloidosis undergoing HDT–ASCT at our center between January 1998 and March 2012. The median age of the patients was 53 years (range, 36–74) with a median follow-up of 35 months (range, 0.4–97 months). Twenty-seven patients (90%) had more than one organ involved besides the heart with 37% with cardiac stage ⩾3. Melphalan-based conditioning regimen (140–200 mg/m2) was used for HDT–ASCT. One-year TRM is 10%. Three-year OS and EFS from HDT–ASCT was 83% and 56.8%, respectively. Cumulative incidence of relapse at 3 years was 38.5%. Negative factors affecting survival included age >60 years, lack of novel induction therapy and BM plasmacytosis >10%. We conclude that HDT–ASCT is well tolerated in patients with high-risk cardiac amyloidosis and can lead to improved overall outcomes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Merlini G, Seldin DC, Gertz MA . Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924–1933.

    Article  Google Scholar 

  2. Kyle RA, Gertz MA . Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59.

    CAS  PubMed  Google Scholar 

  3. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787–1789.

    Article  CAS  Google Scholar 

  4. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751–3757.

    Article  CAS  Google Scholar 

  5. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881–1887.

    Article  CAS  Google Scholar 

  6. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440–2445.

    Article  CAS  Google Scholar 

  7. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989–995.

    Article  CAS  Google Scholar 

  8. Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520–3526.

    Article  CAS  Google Scholar 

  9. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938.

    Article  CAS  Google Scholar 

  10. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Berk JL, Dember LM et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. British journal of haematology 2002; 117: 886–889.

    Article  CAS  Google Scholar 

  11. Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol 2004; 127: 543–551.

    Article  CAS  Google Scholar 

  12. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93.

    Article  CAS  Google Scholar 

  13. Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28: 637–642.

    Article  CAS  Google Scholar 

  14. Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2012; 119: 1117–1122.

    Article  Google Scholar 

  15. Comenzo RL, Gertz MA . Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282.

    Article  CAS  Google Scholar 

  16. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083–1093.

    Article  CAS  Google Scholar 

  17. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319–328.

    Article  Google Scholar 

  18. Kaplan El, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  19. Cox D . Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187–220.

    Google Scholar 

  20. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420–3427.

    Article  CAS  Google Scholar 

  21. Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000; 26: 963–969.

    Article  CAS  Google Scholar 

  22. Girnius S, Seldin DC, Meier-Ewert HK, Sloan JM, Quillen K, Ruberg FL et al. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplant 2014; 49: 434–439.

    Article  CAS  Google Scholar 

  23. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007; 92: 1415–1418.

    Article  Google Scholar 

  24. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391–4394.

    Article  CAS  Google Scholar 

  25. Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013; 31: 4319–4324.

    Article  CAS  Google Scholar 

  26. Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27: 823–828.

    Article  CAS  Google Scholar 

  27. Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007; 139: 224–233.

    Article  CAS  Google Scholar 

  28. Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 2013; 48: 557–561.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    P Kongtim, M H Qazilbash, A Hamdi, N Shah, Q Bashir, R Champlin & S Parmar

  2. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    J J Shah, M Wang, E E Manasanch, D Weber & R Z Orlowski

Authors
  1. P Kongtim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M H Qazilbash
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J J Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Hamdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Q Bashir
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E E Manasanch
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R Z Orlowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Parmar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Parmar.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kongtim, P., Qazilbash, M., Shah, J. et al. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant 50, 668–672 (2015). https://doi.org/10.1038/bmt.2015.21

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.21

This article is cited by

Search

Advanced search

Quick links